Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an update.
Botanix Pharmaceuticals will release 3,111,145 fully paid ordinary shares from voluntary escrow on 20 March 2026, increasing the number of tradable shares on the market. The move may enhance liquidity in Botanix stock and follows the company’s recent progress in commercial dermatology, including its FDA-approved Sofdra treatment for primary axillary hyperhidrosis.
The release of escrowed shares could modestly alter the shareholder base as previously restricted holders gain the ability to trade, though no change in control has been indicated. Investors will be watching how the additional free-float interacts with market demand for Botanix, which is positioning itself around Sofdra as a differentiated therapy in the hyperhidrosis segment.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix in the U.S. The company has received FDA approval for Sofdra, the first and only new chemical entity approved to treat primary axillary hyperhidrosis, addressing an underserved market for patients with excessive underarm sweating.
Average Trading Volume: 9,486,248
Technical Sentiment Signal: Sell
Current Market Cap: A$119.8M
Learn more about BOT stock on TipRanks’ Stock Analysis page.